Dr. Reddy(US:RDY)2026-01-21 16:22Financial Performance - Consolidated revenues for the three months ended December 31, 2025, were Rs. 87,268 million, a 4% increase from Rs. 83,586 million in the same period of 2024[227]. - Gross profit for the same period was Rs. 46,806 million, representing 53.6% of revenues, down from Rs. 49,052 million or 58.7% of revenues in the previous year[243]. - Profit before tax for Q4 2025 was Rs. 15,429 million, down from Rs. 18,742 million in Q4 2024[252]. - Profit for the period in Q4 2025 was Rs. 11,896 million, representing 13.6% of total revenues, compared to Rs. 14,038 million and 16.8% in Q4 2024[254]. - Total revenues for the nine months ended December 31, 2025, were Rs. 260,771 million, an 8% increase from Rs. 240,475 million in the same period of 2024[259]. - Net profit for the period was Rs. 40,261 million for the nine months ended December 31, 2025, representing 15.4% of total revenues, down from 17.2% in the same period of 2024[288]. Revenue Breakdown - Revenues from the Global Generics segment increased by 7% to Rs. 79,113 million, driven by growth in Emerging Markets, Europe, and India[229]. - Revenues from North America decreased by 12% to Rs. 29,644 million, attributed to lower sales prices and volumes of existing products[230]. - Revenues from Europe rose by 20% to Rs. 14,476 million, supported by new product launches and increased sales volumes[233]. - Revenues from India increased by 19% to Rs. 16,032 million, largely due to new product launches and higher sales prices[234]. - Revenues from Emerging Markets surged by 32% to Rs. 18,961 million, with 30 new products launched during the period[237]. - Revenues from the Global Generics segment for the nine months ended December 31, 2025, were Rs. 233,231 million, a 9% increase compared to Rs. 214,187 million in 2024[261]. - Revenues from the Global Generics segment in the "Rest of the World" markets increased by 10% to Rs. 16,422 million for the nine months ended December 31, 2025, compared to Rs. 14,903 million for the same period in 2024[274]. - PSAI segment revenues rose by 6% to Rs. 25,649 million for the nine months ended December 31, 2025, compared to Rs. 24,283 million for the same period in 2024[275]. Expenses - Selling, general and administrative expenses increased by 12% to Rs. 26,918 million in Q4 2025, rising as a percentage of total revenues from 28.9% to 30.8%[246]. - Selling, general and administrative expenses increased by 13% to Rs. 79,001 million for the nine months ended December 31, 2025, representing 30.3% of total revenues[279]. - Research and development expenses decreased by 8% to Rs. 6,149 million in Q4 2025, representing 7.0% of total revenues, down from 8.0% in Q4 2024[247][248]. - Research and development expenses decreased by 8% to Rs. 18,595 million for the nine months ended December 31, 2025, representing 7.1% of total revenues[280][281]. Profitability Metrics - The effective tax rate decreased to 22.9% in Q4 2025 from 25.1% in Q4 2024, with tax expense falling to Rs. 3,533 million from Rs. 4,704 million[253]. - Total gross profit was Rs. 143,573 million for the nine months ended December 31, 2025, representing a gross profit margin of 55.1%, down from 59.5% in the same period of 2024[276]. - For the three months ended December 31, 2025, the total gross profit was Rs. 46,806 million, a decrease from Rs. 49,052 million for the same period in 2024, resulting in a gross profit margin decline from 58.7% to 53.6%[244]. - The gross profit margin for the Global Generics segment decreased to 57.4% in Q4 2025 from 61.3% in Q4 2024, primarily due to price erosion and unfavorable product mix changes[244]. Product Launches and Filings - The company filed four new ANDAs with the U.S. FDA during the period, with 73 filings pending approval as of December 31, 2025[232]. - The company launched six new products in North America and ten new generic products in Europe during the three months ended December 31, 2025[231][233]. - The company launched 18 new products in North America and 31 new generic products in Europe during the nine months ended December 31, 2025[265][267]. Cash Flow and Debt - Net cash from operating activities was Rs. 41,110 million for the nine months ended December 31, 2025, compared to Rs. 24,432 million for the same period in 2024[295]. - Principal debt obligations included short-term borrowings of Rs. 50,286 million as of December 31, 2025[291]. - The company reported a net foreign exchange gain of Rs. 1,510 million for the nine months ended December 31, 2025, compared to a loss of Rs. 403 million for the same period in 2024[286]. Corporate Governance - The shares have been transferred by the Promoters to trusts as per SEBI Order dated December 31, 2024[300]. - The report includes a review by an Independent Registered Public Accounting Firm[301]. - The report was signed by Kumar Randhir Singh, Company Secretary of Dr. Reddy's Laboratories Limited[302].